Nyrada Inc (ASX:NYR)

Nyrada Inc, a clinical-stage biotechnology company, announced the receipt of a notice of allowance from the United States Patent and Trademark Office for its patent application covering the composition of matter of Xolatryp®, a small-molecule inhibitor designed to limit excessive calcium entry related to multiple disease pathologies. The patent will protect Xolatryp's chemical structure in the US, providing intellectual property protection for 20 years from the filing date of September 2024. This milestone is significant for Nyrada as it validates the novelty of Xolatryp and strengthens the company's position in advancing clinical development. Xolatryp has successfully completed a Phase I clinical trial and has commenced a Phase IIa clinical trial targeting patients with acute myocardial infarction to assess safety and preliminary efficacy. This development addresses the unmet medical need for therapies directly targeting ischemia and reperfusion injury.